Synthesis of radioiodinated thymoquinone glucuronide conjugated magnetic nanoparticle (125I-TQG-Fe3 O4) and its cytotoxicity and in vitro affinity

Basit Öğe Kaydı
dc.contributor.authorİnce İ.
dc.contributor.authorBiber Müftüler Z.
dc.contributor.authorMedine E.İ.
dc.contributor.authorGüldü Ö.K.
dc.contributor.authorTekin V.
dc.contributor.authorAktar S.
dc.contributor.authorGöker E.
dc.contributor.authorÜnak P.
dc.date.accessioned2019-10-26T21:15:27Z
dc.date.available2019-10-26T21:15:27Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of the current study is to develop solid, semisolid or liquid form of radionuclide labeled thymoquinone glucuronide conjugated magnetite nanoparticles those targets to the tumor for diagnosis and therapy of cancer. For this purpose, thymoquinone (TQ), a molecule present in the seeds of Nigella (Nigella sativa) used to enhance the affinity of the drug to the tumor cells. TQ was isolated from its microsomes and an enzymatic method applied to synthesize beta glucuronic acid derivatized thymoquinone glucuronide (TQG). TQG attached magnetic nanoparticles (TQG-Fe3 O4). TQG- Fe3 O4 were radiolabeled with 125I and (125I-TQG- Fe3 O4) its cytotoxic effect and in vitro affinity was investigated. The IC50 values of TQG- Fe3 O4 were found 27.31, 18.68, 11.88 (µg/mL) respectively 24, 48 and 72 hours against A549 cell line by WST-8 test as a colorimetric way. Incorporation ratios of TQG- Fe3 O4 with A549 cells is the highest levels. It is seen that TQG-Fe3O4 could inhibit the apoptosis on A549 cells but, there is no apoptotic effect of the samples on BEAS-2B cells. Size distribution, cellular uptake and toxicity characteristics of TQG- Fe3 O4 in this study maintains a useful targeted delivery system in lung cancer diagnosis and therapy. © 2018, İstanbul Medipol University. All rights reserved.en_US
dc.description.sponsorship113S922en_US
dc.description.sponsorshipThis project was financially supported by Turkish Scientific Research Council-Health Sciences Research Support Group (TUBİTAK-SBAG; Project No: 113S922), Ankara, TURKEY. --en_US
dc.identifier.doi10.23893/1307-2080.APS.05608
dc.identifier.endpage26en_US
dc.identifier.issn1307-2080
dc.identifier.issn1307-2080en_US
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage7en_US
dc.identifier.urihttps://doi.org/10.23893/1307-2080.APS.05608
dc.identifier.urihttps://hdl.handle.net/11454/16026
dc.identifier.volume56en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherİstanbul Medipol Universityen_US
dc.relation.ispartofActa Pharmaceutica Scienciaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBeta glucuronidaseen_US
dc.subjectFe3O4en_US
dc.subjectGlucuronide derivativeen_US
dc.subjectMagnetic nanoparticlesen_US
dc.subjectNigella thymoquinone (TQ)en_US
dc.subjectRadiolabeling with 125Ien_US
dc.titleSynthesis of radioiodinated thymoquinone glucuronide conjugated magnetic nanoparticle (125I-TQG-Fe3 O4) and its cytotoxicity and in vitro affinityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu